Zydus Lifesciences Reports Q4FY26 Results; EBITDA Margin Expands To 33.7%, Profit Rises 9% YoY

The Indian equity markets traded lower on Wednesday, with the benchmark Nifty 50 index declining 0.49 per cent to 23,502.75. Pharmaceutical stocks remained in focus amid Q4 earnings announcements and business expansion updates across the sector. In this segment, Zydus Lifesciences gained 5.52 per cent to Rs 1,075.15 after the company announced its Q4FY26 and FY26 consolidated financial results along with a final Dividend recommendation.

Zydus Lifesciences Q4FY26 Results

Zydus Lifesciences reported consolidated revenue from operations of Rs 7,587 crore in Q4FY26 as against Rs 6,528 crore reported in Q4FY25, registering a growth of around 16.2 per cent YoY. Total income from operations stood at Rs 7,587 crore during the quarter compared to Rs 6,528 crore reported in the corresponding quarter previous year.

EBITDA for Q4FY26 stood at Rs 2,554 crore compared to Rs 2,126 crore reported in Q4FY25, reflecting a growth of around 20.2 per cent YoY. EBITDA margin expanded to 33.7 per cent during Q4FY26 as against 32.6 per cent reported in Q4FY25, registering an expansion of 110 basis points YoY.

Profit before Tax stood at Rs 1,660 crore in Q4FY26 compared to Rs 1,672 crore reported in Q4FY25. Profit for the period came in at Rs 1,273 crore during Q4FY26 as against Rs 1,171 crore reported in Q4FY25, reflecting a growth of around 8.7 per cent YoY. Earnings per share stood at Rs 12.65 during Q4FY26 compared to Rs 11.64 reported in Q4FY25

Zydus Lifesciences FY26 Annual Performance

For the financial year ended March 31, 2026, Zydus Lifesciences reported consolidated revenue from operations of Rs 27,148 crore as against Rs 23,241 crore reported in FY25, registering a growth of around 16.8 per cent YoY. EBITDA stood at Rs 8,475 crore during FY26 compared to Rs 7,059 crore reported in FY25, reflecting a growth of around 20.1 per cent YoY. EBITDA margin improved to 31.2 per cent during FY26 as against 30.4 per cent reported in FY25.

Profit before tax stood at Rs 6,621 crore during FY26 compared to Rs 6,027 crore reported in FY25, reflecting a growth of around 9.9 per cent YoY. Profit for the period came in at Rs 5,040 crore during FY26 as against Rs 4,526 crore reported in FY25, registering a growth of around 11.4 per cent YoY.

Segment And Business Highlights

The pharmaceuticals segment remained the largest contributor to revenue, reporting segment revenue of Rs 22,412 crore during FY26, while the consumer products segment contributed Rs 3,954 crore. The medical technologies segment also contributed Rs 782 crore during the financial year.

During FY26, the company completed multiple strategic acquisitions including Amplitude Surgical SA and Comfort Click Limited to strengthen its medical technologies and consumer wellness businesses. Zydus also announced acquisition plans for Assertio Holdings in the US market.

Buyback Update & Dividend Announcement

The Board approved a share buyback of up to Rs 1,100 crore at a price of Rs 1,150 per equity share, representing a premium of around 16 per cent over the closing share price on May 18, 2026. Further, the Board of Directors recommended a final dividend of Re 1 per equity share having face value of Re 1 each for FY26, subject to shareholders’ approval at the upcoming Annual General Meeting.

About Zydus Lifesciences

Zydus Lifesciences Ltd is a leading Indian pharmaceutical company engaged in manufacturing and marketing formulations, biologics, vaccines, consumer wellness products and active pharmaceutical ingredients across domestic and international markets.

What are your views on Zydus Lifesciences’ Q4FY26 performance and its expansion across medical technologies and consumer wellness businesses? Share your thoughts in the comments below.
Disclaimer: This article is for informational purposes only and not investment advice.